VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
Arquer Diagnostics @Arquer Diagnostics
Those who undergo successful #treatment for #bladder #cancer are at risk of #recurrence for many years afterwards. Routine visits to your urologist are vital to stay on the right path: it's here that #ADXBLADDER can be a really useful tool for the detection of recurrence. https://t.co/wllXtQmQ4v
Arquer Diagnostics @Arquer Diagnostics
4/5 #patients are referred to #urologists due to #haematuria. When #bladdercancer is suspected, #urologists can use #ADXBLADDER in conjunction with #cystoscopic procedures for a more confident and accurate #diagnosis of bladder cancer.
https://t.co/w5aGQqfIVQ
#Arquer #urology https://t.co/NkYisrtHdV
Arquer Diagnostics @Arquer Diagnostics
With an #NPV of 99.5% #ADXBLADDER makes it easy for #urologists to identify #bladdercancer recurrence. Our quick #urine test can reduce the need for unnecessary #cystocopies, meaning shortened waiting lists and fewer expensive, unpleasant procedures.
https://t.co/FhOvCtBxtO https://t.co/v4UKQBL3JI
Arquer Diagnostics @Arquer Diagnostics
Hello #Venice! #Arquer Diagnostics and #Pantec SRL are in attendance at the 92nd Annual Italian #Urology Congress.
https://t.co/FhOvCtBxtO https://t.co/XCqoUQcLMt
Arquer Diagnostics @Arquer Diagnostics
99.5% is the measure of the ability of our #ADXBLADDER technology to exclude the presence of a bladder cancer tumour (excl. non LGpTa). Find out more about how we're helping #urology and #cancerpatients worldwide: https://t.co/FhOvCtBxtO
#Arquer https://t.co/za2WQF270r
